IL5 and asthma: We observed significant reductions in the reporting of sinusitis (OR = 0.75; 95 % CI from 0.53 to 1.06), bronchitis (OR = 0.71; 95 % CI from 0.59 to 0.86), and ED or hospital admission due to asthma exacerbation for overall <i>anti</i>-IL-5 antibodies compared to placebo (OR = 0.59; 95 % CI from 0.40 to 0.88).